Citadel Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Citadel Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12,500	Closed	-$53K	–	9995
2018 Q2	$53K	Buy	+12,500	New	+$63K	﹤0.01%	8428
2017 Q3	–	Sell	-14,100	Closed	-$102K	–	8352
2017 Q2	$102K	Sell	14,100 -9,300	-40%	-$57.2K	﹤0.01%	6903
2017 Q1	$124K	Buy	+23,400	New	+$158K	﹤0.01%	6780

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Citadel Advisors's PETX Position: Q3 2019 in Review

Citadel Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 30,557 shares — an estimated $158K sold.

Citadel Advisors first reported a position in PETX in Q3 2014 and held it in 16 quarters. The position peaked at $809K in Q4 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Citadel Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Citadel Advisors sold 30,557 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $158K.
Citadel Advisors first reported a position in Aratana Therapeutics, Inc. in Q3 2014 and held it in 16 quarters.
Citadel Advisors's Aratana Therapeutics, Inc. position peaked at $809K in Q4 2015.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.